Transamerica Financial Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Transamerica Financial Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.6K	Hold	36	–	–	﹤0.01%	999
2026 Q1	$8.23K	Buy	+36	New	+$8.07K	﹤0.01%	959
2025 Q4	–	Sell	-1	Closed	-$199	–	1834
2025 Q3	$199	Buy	+1	New	+$187	﹤0.01%	1442

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Transamerica Financial Advisors's ASND Position: Q2 2026 in Review

Transamerica Financial Advisors held its Ascendis Pharma A/S (ASND) position steady in Q2 2026 at 36 shares worth $9.6K. The position accounts for ﹤0.01% of the portfolio, ranked #999.

Transamerica Financial Advisors first reported a position in ASND in Q3 2025 and has held it in 3 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Transamerica Financial Advisors held 36 shares of Ascendis Pharma A/S worth $9.6K as of Q2 2026.
Transamerica Financial Advisors left its Ascendis Pharma A/S share count unchanged in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #999 holding.
Transamerica Financial Advisors first reported a position in Ascendis Pharma A/S in Q3 2025 and has held it in 3 quarters since.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.